NCT06692322View on ClinicalTrials.gov

A Study to Test How Zongertinib is Taken up in the Blood of People With and Without Liver Problems

PHASE1CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

January 15, 2025

Primary Completion Date

June 20, 2025

Study Completion Date

June 20, 2025

Conditions
Liver DiseasesHealthy
Interventions
DRUG

Zongertinib (BI 1810631)

Film-coated tablet

Trial Locations (1)

78215

American Research Corporation at the Texas Liver Institute, San Antonio

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY